Bayer takes BNP (B-type natriuretic peptide) assay to smaller laboratories:
This article was originally published in Clinica
Executive Summary
Bayer Diagnostics is expanding the availability of its BNP assay, used to help diagnose heart failure, to small-volume laboratories. After launching the test in the US in 2003 for use on the ADVIA Centaur system used in larger labs, the company is now offering it for use on the ACS:180 immunoassay system in the US and other markets. BNP (B-type natriuretic peptide) testing is gathering pace following findings that elevated levels in the blood can indicate heart failure. Similar tests are already offered in the US by Roche Diagnostics and Biosite, and several others are being developed by other companies.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.